



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee October 2023 Meeting Outcome

| | Generic name | Brand name | Therapeutic Class | Meeting outcome | Primary reason for rejection ¹ |
|----|----------------------------|-------------------|---|-----------------|---|
| 1 | Abrocitinib | Cibinqo | Skin | Approved | |
| 2 | Amivantamab | Rybrevent | Malignant disease and immunosuppression | Rejected | Insufficient evidence to demonstrate significant clinical outcome benefits |
| 3 | Anifrolumab | Saphnelo | Musculoskeletal and joint disease | Approved | |
| 4 | Cinacalcet | Regpara | Nutrition and blood | Approved | |
| 5 | Daratumumab / Lenalidomide | Darzalex/Revlimid | Malignant disease and immunosuppression | Rejected | Insufficient evidence to demonstrate significant clinical outcome benefits |
| 6 | Dexamethasone | Ozurdex | Eye | Pending | |
| 7 | Dostarlimab | Jemperli | Malignant disease and immunosuppression | Pending | |
| 8 | Dupilumab | Dupixent | Ear, nose, and oropharynx | Approved | |
| 9 | Empagliflozin | Jardiance | Endocrine system | Approved | |
| 10 | Entrectinib | Rozlytrek | Malignant disease and immunosuppression | Rejected | The justification of the treatment's cost in relation to its benefits is insufficient |
| 11 | Fremanezumab | Ajovy | Central nervous system | Approved | |
| 12 | Insulin glargine | Toujeo | Endocrine system | Pending | |
| 13 | Lenalidomide | Revlimid | Malignant disease and immunosuppression | Approved | |
| 14 | Lenvatinib / Pembrolizumab | Lenvima/Keytruda | Malignant disease and immunosuppression | Approved | |
| 15 | Lorlatinib | Lorviqua | Malignant disease and immunosuppression | Approved | |
| 16 | Mepolizumab | Nucala | Ear, nose, and oropharynx | Rejected | Insufficient comparative studies versus existing treatment |
| 17 | Migalastat | Galafold | Nutrition and blood | Approved | |
| 18 | Nintedanib | Ofev | Respiratory system | Approved | |

| | Generic name | Brand name | Therapeutic Class | Meeting outcome | Primary reason for rejection¹ |
|----|--------------------------|-------------------|---|------------------------|--|
| 19 | Niraparib | Zejula | Malignant disease and immunosuppression | Rejected | Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population |
| 20 | Nivolumab | Opdivo | Malignant disease and immunosuppression | Approved | |
| 21 | Nivolumab / Ipilimumab | Opdivo / Yervoy | Malignant disease and immunosuppression | Rejected | Insufficient evidence to demonstrate significant clinical outcome benefits |
| 22 | Onasemnogene abeparvovec | Zolgensma | Musculoskeletal and joint disease | Pending | |
| 23 | Osimertinib | Tagrisso | Malignant disease and immunosuppression | Approved | |
| 24 | Secukinumab | Cosentyx | Skin | Approved | |
| 25 | Selumetinib | Koselugo | Malignant disease and immunosuppression | Approved | |
| 26 | Tisagenlecleucel | Kymriah | Malignant disease and immunosuppression | Pending | |
| 27 | Trastuzumab | Kanjinti | Malignant disease and immunosuppression | Approved | |
| 28 | Trastuzumab | Herzuma | Malignant disease and immunosuppression | Approved | |
| 29 | Vericiguat | Verquvo | Cardiovascular system | Rejected | The justification of the treatment's cost in relation to its benefits is insufficient |

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.